3 CDK 4/6 inhibitors (palbociclib, ribociclib, and abemaciclib)have been approved for HER2-negative metastatic breast cancers. CDK 4/6 inhibitors help overcome resistance to endocrine therapies by preventing cell-cycle progression and cancer growth (frontiersin.org/articles/10.33…).
What do we know about AKI related to CDK 4/6 inhibition? In vitro studies suggest that CDK 4/6 inhibitor metabolites inhibit renal transporters, potentially leading to a reversible rise in serum creatinine (SCr) without actually changing GFR (ncbi.nlm.nih.gov/pmc/articles/P…).
Our objective: to present the first series of patients with biopsy-proven AKI associated with CDK4/6 inhibitors, with a focus on clinical features and pathologic findings, and to query the FAERS database for renal adverse events related to CDK 4/6 inhibitors
Histopathology: 6 patients treated at 3 different centers had biopsy-proven AKI that was directly attributable to the CDK 4/6 inhibitor by the treating nephrologist. Acute tubular injury was the most common pathology, though one patient had acute tubulointerstitial nephritis
Repercussions of AKI: AKI required dose reduction and or discontinuation of therapy in 4 of 6 patients
Reporting of renal related adverse events: The most common renal adverse event was renal injury, but electrolyte abnormalities were reported as well, including hypokalemia, hyponatremia, and hypocalcemia
Though CDK4/6 inhibitors may lead to a reversible rise in SCr, they can also cause true renal tubular toxicity and metabolic disturbances. We now need larger, prospective studies to understand and characterize the incidence of and risk factors for AKI
Why does it matter? ICPi-AKI can lead to:
*Discontinuation of ICPi therapy
*Irreversible loss of kidney function
*Prolonged courses of immunosuppression (2/11)
We conducted a multicenter study of 429 patients with ICPi-AKI from 30 sites across 10 countries, along with 429 control patients who received ICPis contemporaneously but did not develop ICPi-AKI. This is the largest study to date on ICPi-AKI (3/11)